{"id":135293,"date":"2026-09-23T20:06:08","date_gmt":"2026-09-23T20:06:08","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/135293\/"},"modified":"2026-09-23T20:06:08","modified_gmt":"2026-09-23T20:06:08","slug":"is-roche-holding-swxrop-undervalued-following-its-phase-3-iga-nephropathy-win","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/135293\/","title":{"rendered":"Is Roche Holding (SWX:ROP) Undervalued Following Its Phase 3 IgA Nephropathy Win?"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Roche Holding (SWX:ROP) is back in focus after partner Ionis reported that sefaxersen met the primary endpoint in the Phase 3 IMAgINATION trial for IgA nephropathy, delivering a statistically significant reduction in proteinuria compared with placebo.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The latest clinical headlines come on top of a strong run for Roche Holding, with the share price up 8.32% over 90 days and 11.58% year to date. The 1-year total shareholder return of 44.02% points to momentum that has been building rather than fading.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"> Capitalize on the momentum around Roche Holding and this latest clinical win by scanning a hand-picked <a href=\"https:\/\/simplywall.st\/discover\/investing-ideas\/434426\/healthcare-ai\/global?utm_medium=finance_user&amp;utm_campaign=cta_screener_healthcare_ai&amp;utm_source=yahoo&amp;blueprint=4761927\" data-ylk=\"slk:133%20healthcare%20AI%20stocks;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;133 healthcare AI stocks&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">133 healthcare AI stocks<\/a> that are also leaning hard into data, diagnostics, and next-wave biotech platforms.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Roche Holding now trades only about 3% below the average analyst target, yet screens at a roughly 59% discount to an intrinsic value estimate. Is the market prudently fading the rally, or overstating the risks in that gap?  <\/p>\n<p>        Most Popular Narrative: 2.8% Overvalued          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The current Roche Holding share price of CHF363.20 sits slightly above the most followed narrative fair value of CHF353.34, which pegs the stock as only marginally rich against its estimated cash flow stream.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Roche is a high-quality, cash-generative pharma leader with:  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2705 Strong fundamentals:  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 $80B revenue scale  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 ~$26B EBITDA  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 ~30% margins  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2705 Attractive profile:  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 Defensive + dividend (~3%)  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 Deep pipeline with multiple catalysts  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u26a0\ufe0f Constraints:  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 Moderate growth vs biotech  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 Clinical execution risk  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\ud83d\udc49 Final view:  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 Core holding (defensive healthcare allocation)  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 Moderate upside (+10 to 20%) driven by pipeline  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 Suitable for long-term investors seeking stability and innovation exposure  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">See why <a href=\"https:\/\/www.simplywall.st\/narratives\/079a3olg-roche-is-a-cash-generating-defensive-large-cap-pharma-with-upside-driven-by-pipeline-execution?utm_medium=finance_user&amp;utm_campaign=cta_narrative_prompt_after_quote&amp;utm_source=yahoo\" data-ylk=\"slk:4%20investors%20see%20Roche%20Holding%20as%203%25%20overvalued;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;4 investors see Roche Holding as 3% overvalued&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">4 investors see Roche Holding as 3% overvalued<\/a>.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Result: Fair Value of CHF353.34 (OVERVALUED)  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Still, the Roche Holding story can change quickly if key Phase 3 programs disappoint or if biosimilar pressure on older blockbusters accelerates faster than expected.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Find out about the <a href=\"https:\/\/www.simplywall.st\/company\/id\/04515585-96e8-4172-bae3-19cc35b27fd4?utm_medium=finance_user&amp;utm_campaign=risks_narrative_cta&amp;utm_source=yahoo\" data-ylk=\"slk:key%20risks%20to%20this%20Roche%20Holding%20narrative;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;key risks to this Roche Holding narrative&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">key risks to this Roche Holding narrative<\/a>.  <\/p>\n<p>            Another View on Roche Holding&#8217;s Valuation          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The narrative fair value suggests Roche Holding is slightly overvalued at CHF363.20 versus CHF353.34. The SWS DCF model points in the opposite direction. On that measure, the shares trade at a steep discount to an estimated future cash flow value of CHF893.70, which raises the question of whether the market is pricing too much risk into a business with this earnings profile.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">For investors who want to see how that result is built up step by step, <a href=\"https:\/\/www.simplywall.st\/company\/id\/04515585-96e8-4172-bae3-19cc35b27fd4\/valuation?utm_medium=finance_user&amp;utm_campaign=alternate_dcf_cta&amp;utm_source=yahoo\" data-ylk=\"slk:Look%20into%20how%20the%20SWS%20DCF%20model%20arrives%20at%20its%20fair%20value.;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Look into how the SWS DCF model arrives at its fair value.&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Look into how the SWS DCF model arrives at its fair value.<\/a>  <\/p>\n<p>     <a href=\"https:\/\/www.simplywall.st\/company\/id\/04515585-96e8-4172-bae3-19cc35b27fd4\/valuation?utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"ROP Discounted Cash Flow as at Sep 2026\" height=\"428\" width=\"960\" class=\"yf-1f8hkhu loader\"\/><\/a> ROP Discounted Cash Flow as at Sep 2026          Next Steps         <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Mixed signals on Roche Holding&#8217;s value and risk profile can either feel like noise or a useful prompt. Move quickly, review the numbers, weigh the concerns against the potential upside, and then anchor your own stance with the help of <a href=\"https:\/\/www.simplywall.st\/stocks\/ch\/pharmaceuticals-biotech\/vtx-rop\/roche-holding-shares?utm_medium=finance_user&amp;utm_campaign=cta_risks_rewards_analysis&amp;utm_source=yahoo\" data-ylk=\"slk:3%20key%20rewards%20and%201%20important%20warning%20sign;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;3 key rewards and 1 important warning sign&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">3 key rewards and 1 important warning sign<\/a>  <\/p>\n<p>       Looking for more Roche Holding style investment ideas?         <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">If Roche Holding has sharpened your focus, do not stop here. Broaden your watchlist with other high quality opportunities that could complement your current thinking.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Companies discussed in this article include <a href=\"https:\/\/finance.yahoo.com\/quote\/ROP.SW\" data-ylk=\"slk:ROP.SW;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;ROP.SW&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"nofollow noopener\">ROP.SW<\/a>.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Have feedback on this article? Concerned about the content? <a href=\"https:\/\/investor-research.typeform.com\/to\/wvg6MFri#feedback_token=NDc2MTkyNzphN2M4NTUxNWQ0MTZjODYz&amp;company=SWX:ROP&amp;blueprintid=4761927\" data-ylk=\"slk:Get%20in%20touch;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Get in touch&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Get in touch<\/a> with us directly. Alternatively, email <a href=\"https:\/\/uk.finance.yahoo.com\/news\/mailto:editorial-team@simplywallst.com?subject=Re%3A%20Your%20article%20on%20SWX%3AROP%20(yahoo)%20from%2023rd%20September%202026\" data-ylk=\"slk:editorial-team%40simplywallst.com;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;editorial-team@simplywallst.com&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">editorial-team@simplywallst.com<\/a>  <\/p>\n","protected":false},"excerpt":{"rendered":"Roche Holding (SWX:ROP) is back in focus after partner Ionis reported that sefaxersen met the primary endpoint in&hellip;\n","protected":false},"author":2,"featured_media":135294,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[1104,134,994],"class_list":["post-135293","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-fair-value","tag-roche","tag-roche-holding"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117322159618595935","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/135293","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=135293"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/135293\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/135294"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=135293"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=135293"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=135293"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}